NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









R1 Therapeutics

R1 Therapeutics

Private
Redwood City, CaliforniaHealthcare & Life Scienceshttps://r1therapeutics.com/

Last Round

Series A

Mar 17, 2026

Total Funding Raised

$77.5M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

R1 Therapeutics is a biotechnology company that develops first-in-class therapies for patients with kidney disease.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologydrug discoverytherapeutic developmentbiotechsmall-molecule therapyclinical-stage biotechhyperphosphatemiadrug pipelinebiopharmalicensing agreementlife sciencesR&D

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

R1 Therapeutics Comps

Public and private peers based on sector, stage, and business model.

R1 Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

R1 Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AMar 17, 2026

Key People

Founding team and executive leadership

Krishna Polu

President and CEO

Executive Team

L Mary Smith

Chief Operating Officer

Executive Team

R1 Therapeutics Investors

Notable investors and investment history

R1 Therapeutics investors
InvestorRounds
SymBiosis Capital ManagementSeries A
AbingworthSeries A
F-Prime CapitalSeries A
DaVita Venture GroupSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 17, 2026

    $78M round completed.

R1 Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

R1 Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about R1 Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersRedwood City, California
Employee Range14
Year Founded2026
Last FundingMar 17, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.